Non-invasive Tests for Non-alcoholic Steato-hepatitis

The main objective is to study and validate a new approach for NASH and liver fibrosis diagnosis and personalized follow-up based on monocyte biomarkers and plasma metabolites. The investigators will assess if PLIN2 and RAB14 can be used not only to identify subjects with NASH and advanced fibrosis but also for monitoring the effect of treatment alone or in combination with other metabolic parameters

NCT Number	NCT07502755
Lead Sponsor	Fondazione Policlinico Universitario Agostino Gemelli IRCCS Collaborators: National Research Council, Institute of Clinical Physiology, Italy, Azienda Ospedaliera Universitaria Mater Domini, Catanzaro, Federico II University
Conditions	NASH With Fibrosis, Diabete Type 2, Obesity
Enrollment	828 participants
Start Date	2024-08-31
Primary Completion	2027-02-28 (estimated)
Study Completion	2027-02-28 (estimated)
Updated on ClinicalTrials.gov	2026-03-31